24 research outputs found

    Effects of eight neuropsychiatric copy number variants on human brain structure

    Get PDF
    Many copy number variants (CNVs) confer risk for the same range of neurodevelopmental symptoms and psychiatric conditions including autism and schizophrenia. Yet, to date neuroimaging studies have typically been carried out one mutation at a time, showing that CNVs have large effects on brain anatomy. Here, we aimed to characterize and quantify the distinct brain morphometry effects and latent dimensions across 8 neuropsychiatric CNVs. We analyzed T1-weighted MRI data from clinically and non-clinically ascertained CNV carriers (deletion/duplication) at the 1q21.1 (n = 39/28), 16p11.2 (n = 87/78), 22q11.2 (n = 75/30), and 15q11.2 (n = 72/76) loci as well as 1296 non-carriers (controls). Case-control contrasts of all examined genomic loci demonstrated effects on brain anatomy, with deletions and duplications showing mirror effects at the global and regional levels. Although CNVs mainly showed distinct brain patterns, principal component analysis (PCA) loaded subsets of CNVs on two latent brain dimensions, which explained 32 and 29% of the variance of the 8 Cohen’s d maps. The cingulate gyrus, insula, supplementary motor cortex, and cerebellum were identified by PCA and multi-view pattern learning as top regions contributing to latent dimension shared across subsets of CNVs. The large proportion of distinct CNV effects on brain morphology may explain the small neuroimaging effect sizes reported in polygenic psychiatric conditions. Nevertheless, latent gene brain morphology dimensions will help subgroup the rapidly expanding landscape of neuropsychiatric variants and dissect the heterogeneity of idiopathic conditions

    Incidence and Risk Factors of Retro-Orbital Embolic Central Retinal Artery Occlusions

    No full text
    This retrospective study describes the incidence of retro-orbital emboli as a source of central retinal artery occlusion (CRAO) as detected by orbital color Doppler imaging (OCDI) in an eye emergency department. We additionally report association of retro-orbital embolic (ROE) events with vasculopathic risk factors and rates of co-incident cerebral vascular ischemia as assessed by MRI imaging

    Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials.

    Get PDF
    Individuals with schizophrenia show increased smoking rates which may be due to a beneficial effect of nicotine on cognition and information processing. Decreased amplitude of the P50 and N100 auditory event-related potentials (ERPs) is observed in patients. Both measures show normalization following administration of nicotine. Recent studies identified an association between deficits in auditory evoked gamma oscillations and impaired information processing in schizophrenia, and there is evidence that nicotine normalizes gamma oscillations. Although the role of nicotine receptor subtypes in augmentation of ERPs has received some attention, less is known about how these receptor subtypes regulate the effect of nicotine on evoked gamma activity.We examined the effects of nicotine, the α7 nicotine receptor antagonist methyllycaconitine (MLA) the α4β4/α4β2 nicotine receptor antagonist dihydro-beta-erythroidine (DHβE), and the α4β2 agonist AZD3480 on P20 and N40 amplitude as well as baseline and event-related gamma oscillations in mice, using electrodes in hippocampal CA3. Nicotine increased P20 amplitude, while DHβE blocked nicotine-induced enhancements in P20 amplitude. Conversely, MLA did not alter P20 amplitude either when presented alone or with nicotine. Administration of the α4β2 specific agonist AZD3480 did not alter any aspect of P20 response, suggesting that DHβE blocks the effects of nicotine through a non-α4β2 receptor specific mechanism. Nicotine and AZD3480 reduced N40 amplitude, which was blocked by both DHβE and MLA. Finally, nicotine significantly increased event-related gamma, as did AZD3480, while DHβE but not MLA blocked the effect of nicotine on event-related gamma.These results support findings showing that nicotine-induced augmentation of P20 amplitude occurs via a DHβE sensitive mechanism, but suggests that this does not occur through activation of α4β2 receptors. Event-related gamma is strongly influenced by activation of α4β2, but not α7, receptor subtypes, while disruption of N40 amplitude requires the activation of multiple receptor subtypes

    Nicotine receptor subtype-specific effects on the P20 component of the ERP.

    No full text
    <p><b>A</b>) P20 amplitude following nicotine and nicotine receptor antagonists. Assessment of the effects of nicotine antagonists was carried out using a within subjects design in which each mouse was assessed on each drug, with sessions being separated by a 24 hour washout period. N = 13 for each condition. Nicotine (1 mg/kg) produced a significant increase in P20 S1 (black) amplitude without concomitant changes in S2 (gray). The α4β4/α4β2 nicotinic receptor antagonist DHβE (2 mg/kg) blocked the effect of nicotine on P20 amplitude, while the α7 antagonist MLA (10 mg/kg) had no effect on P20. S1 was significantly higher than S2 in all conditions except nicotine plus DHβE. <b>B</b>) <b>P20 amplitude following the α4β2 specific agonist AZD3480.</b> Assessment of the effects of AZD3480 was carried out using a within subjects design in which each mouse was assessed on each drug, with sessions being separated by a 72 hour washout period. The mice used to assess AZD3480 were a separate cohort from those shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0039775#pone-0039775-g002" target="_blank">Figure 2A</a> used to assess nicotine antagonists. N = 9 for each condition. No significant changes were observed on P20 amplitude following either a low (1 mg/kg) or high (10 mg/kg) dose of the α4β2 AZD3480 antagonist. # indicates significant difference from saline vehicle (all p<0.05).</p

    Nicotine receptor subtype-specific effects on auditory evoked gamma oscillations.

    No full text
    <p>(Top) Event-related Gamma (30 to 80 Hz) activity following nicotine and nicotine receptor antagonists. Assessment of the effects of nicotine antagonists was carried out using a within subjects design in which each mouse was assessed on each drug, with sessions being separated by a 24 hour washout period. N = 13 for each condition. Depicted top left <b>A</b>) is the average event-related gamma power (in dB) for the period between 0 and 60 msec following stimulus onset, across all 50 stimulus presentations. This was done by calculating the time-frequency response for each wavelet cycle within the 0 to 60 msec period and averaging the resulting values to create a single number. All statistical analyses were conducted on these values. Nicotine (1 mg/kg) caused an increase in evoked gamma activity, which was blocked by DHβE (2 mg/kg) but not MLA (10 mg/kg), indicating that the positive effect of nicotine on gamma activity is mediated through the α4β2 receptor subtype. # indicates p<0.05. Top center <b>B</b>) depicts event-related gamma power across each individual wavelet cycle between 100 msec pre-stimulus and 200 msec post-stimulus across all 50 stimulus presentations. Depicted top left <b>C</b>) is a heat map showing event-related power in decibels (event-related spectral perturbation, i.e. the power following the stimulus expressed as a change from baseline) from 200 msec prior to stimulus onset to 200 msec post onset (0 = stimulus onset) across all 50 stimulus presentations following vehicle and nicotine treatment. (Bottom) Event-related Gamma activity following administration of the α4β2 specific agonist AZD3480. Assessment of the effects of AZD3480 was carried out using a within subjects design in which each mouse was assessed on each drug, with sessions being separated by a 72 hour washout period. The mice used to assess AZD3480 were a separate cohort from those shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0039775#pone-0039775-g002" target="_blank">Figure 2A</a> used to assess nicotine antagonists. N = 9 for each condition. Bottom left D) shows a significant increase in event-related gamma following low (1 mg/kg), but not high (10 mg/kg) dose AZD3480. The methodology used to create bottom left <b>D</b>), center <b>E</b>) and right <b>F</b>) figures are the same used to create figures <b>A</b>, <b>B</b> and <b>C</b>, respectively. # - indicates significant differences from saline vehicle (all p<0.05).</p
    corecore